Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
301 studies found for:    nasopharyngeal cancer | "Nasopharyngeal Neoplasms"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
nasopharyngeal cancer | "Nasopharyngeal Neoplasms"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer
Condition: Nasopharyngeal Neoplasms
Intervention: Drug: EBV-LMP-2
2 Completed Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Condition: Nasopharyngeal Neoplasms
Intervention: Drug: Sorafenib plus Cisplatin and 5-fluorouracil
3 Recruiting Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)
Condition: Nasopharyngeal Neoplasms
Interventions: Biological: Pembrolizumab;   Drug: Capecitabine;   Drug: Gemcitabine;   Drug: Docetaxel
4 Unknown † Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
Conditions: Nasopharyngeal Neoplasms;   Carcinoma, Squamous Cell
Interventions: Procedure: Conventional RT;   Drug: Cisplatin;   Drug: 5-fluorouracil
5 Terminated Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)
Conditions: Nasopharyngeal Neoplasms;   Carcinoma, Squamous Cell
Interventions: Procedure: Conventional RT;   Procedure: Accelerated RT;   Drug: Cisplatin;   Drug: 5-fluorouracil
6 Completed Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function
Condition: Nasopharyngeal Neoplasms
Intervention: Procedure: Intensity-modulated radiation therapy
7 Active, not recruiting Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Neoplasms
Intervention: Drug: CC-486
8 Unknown † Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer
Condition: Nasopharyngeal Neoplasms
Interventions: Procedure: Conventional Radiotherapy;   Procedure: Accelerated Radiotherapy;   Drug: Cisplatin;   Drug: 5-fluorouracil;   Drug: Capecitabine
9 Completed Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Neoplasms
Interventions: Drug: Docetaxel;   Drug: Cisplatin;   Drug: Capecitabine
10 Active, not recruiting Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Neoplasms
Interventions: Drug: gemcitabine and cisplatin;   Drug: 5-Fluorouracil and cisplatin
11 Recruiting Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Carboplatin
12 Not yet recruiting ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Condition: Nasopharyngeal Neoplasms
Interventions: Drug: Apatinib;   Drug: Placebo
13 Recruiting Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Neoplasms
Interventions: Radiation: IMRT using individualized CTV;   Radiation: IMRT using traditional CTV;   Drug: Gemcitabine and cisplatin (induction chemotherapy);   Drug: Docetaxel and cisplatin (induction chemotherapy);   Drug: Cisplatin 100mg/m² concurrent chemotherapy;   Drug: Cisplatin 80mg/m² concurrent chemotherapy
14 Unknown † Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Neoplasms
Intervention: Drug: ABX + DDP
15 Completed
Has Results 		Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
Conditions: Nasopharyngeal Neoplasms;   Carcinoma
Interventions: Drug: docetaxel;   Drug: cisplatin;   Drug: 5-fluorouracil
16 Not yet recruiting Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
Conditions: Nasopharyngeal Neoplasms;   Stomatitis
Interventions: Drug: Oral Ulcer Gargle (FORRAD®);   Drug: Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine
17 Not yet recruiting Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
Conditions: Nasopharyngeal Neoplasms;   Radiodermatitis
Interventions: Drug: Medical Radiation Protectants (FORRAD®);   Drug: Trolamine (Biafine)
18 Completed Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy
Condition: Nasopharyngeal Neoplasms
Intervention: Drug: Pemetrexed (Alimta)
19 Recruiting Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Neoplasms;   Blood Cell Count;   Neoplasm Staging;   Prognosis
Intervention:
20 Active, not recruiting Intensity Modulated Radiation Therapy for Head and Neck Cancer
Condition: Nasopharyngeal Neoplasms
Interventions: Procedure: intensity modulated radiation therapy;   Drug: cisplatinium and fluorouracil - standard treatment
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years